Method for treating a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate
The present invention is directed to a method for inducing UGT1A1 isoform expression for treatment of a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate comprising the step of administering to a subject an effective amount of ritonavir. In particular, the present invention is directed to a method of treating unconjugated hyperbilirubinemia by UGT1A1 induction comprising the step of administering to a subject an effective amount of ritonavir.
1. A method for treating a disease, disorder, or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate upon administration of atazanavir comprising the step of co-administering ritonavir in an effective amount to a subject in need thereof.
2. The method of claim 1 , wherein the effective amount of ritonavir is in a range of about 25 mg to about 1200 mg.
3. The method of claim 1 , wherein the disease, disorder, or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate is unconjugated hyperbilirubinemia.
4. The method of claim 1 , wherein the UGT1A1 substrate is bilirubin.